EGFR and diffuse midline glioma: Taking into account these recent discoveries, which are of paramount biological importance, the 2021 WHO classification of CNS tumors (fifth edition) adopted the revised designation “diffuse midline glioma, H3K27-altered” to include subtypes of DMG with an alternative mechanism for the loss of H3K27 trimethylation (EZHIP overexpression DMG, EGFR mutant DMG), in addition to the most common H3K27M mutation (3).